3/27
08:02 am
olma
Olema Pharmaceuticals (OLMA) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Olema Pharmaceuticals (OLMA) is now covered by Wolfe Research. They set a "peer perform" rating on the stock.
3/24
10:53 am
olma
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me” [Yahoo! Finance]
Low
Report
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me” [Yahoo! Finance]
3/23
11:38 am
olma
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility [Yahoo! Finance]
Low
Report
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility [Yahoo! Finance]
3/22
12:36 pm
olma
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? [Yahoo! Finance]
Low
Report
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? [Yahoo! Finance]
3/19
09:02 am
olma
Olema Pharmaceuticals (OLMA) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Olema Pharmaceuticals (OLMA) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/18
11:48 am
olma
Olema Pharmaceuticals (OLMA) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00. They now have an "overweight" rating on the stock.
Low
Report
Olema Pharmaceuticals (OLMA) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00. They now have an "overweight" rating on the stock.
3/18
11:31 am
olma
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Low
Report
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
3/18
08:03 am
olma
Olema Pharmaceuticals (OLMA) had its price target lowered by The Goldman Sachs Group, Inc. from $38.00 to $27.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (OLMA) had its price target lowered by The Goldman Sachs Group, Inc. from $38.00 to $27.00. They now have a "buy" rating on the stock.
3/17
04:30 pm
olma
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Low
Report
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
3/17
12:30 pm
olma
Olema Pharmaceuticals (OLMA) had its price target raised by Citigroup Inc. from $60.00 to $62.00. They now have a "buy" rating on the stock.
Low
Report
Olema Pharmaceuticals (OLMA) had its price target raised by Citigroup Inc. from $60.00 to $62.00. They now have a "buy" rating on the stock.
3/17
09:03 am
olma
Olema Pharmaceuticals (OLMA) had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (OLMA) had its price target lowered by Guggenheim from $40.00 to $38.00. They now have a "buy" rating on the stock.
3/16
07:11 pm
olma
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch [Yahoo! Finance]
Medium
Report
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch [Yahoo! Finance]
3/16
07:43 am
olma
Olema Pharmaceuticals GAAP EPS of -$0.50 beats by $0.01 [Seeking Alpha]
Medium
Report
Olema Pharmaceuticals GAAP EPS of -$0.50 beats by $0.01 [Seeking Alpha]
3/16
07:00 am
olma
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
High
Report
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
3/12
08:44 pm
olma
A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback [Yahoo! Finance]
Low
Report
A Look At Olema Pharmaceuticals (OLMA) Valuation After Roche Breast Cancer Trial Setback And Share Price Pullback [Yahoo! Finance]
3/10
11:29 am
olma
H.C. Wainwright does not see direct read from Roche miss to Olema's OPERA-02 [Yahoo! Finance]
Medium
Report
H.C. Wainwright does not see direct read from Roche miss to Olema's OPERA-02 [Yahoo! Finance]
3/9
01:57 pm
olma
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
Medium
Report
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
3/9
01:06 pm
olma
Olema Pharmaceuticals (OLMA) had its "buy" rating reaffirmed by TD Cowen.
Medium
Report
Olema Pharmaceuticals (OLMA) had its "buy" rating reaffirmed by TD Cowen.
3/9
12:15 pm
olma
Olema Pharmaceuticals (OLMA) had its price target lowered by HC Wainwright from $45.00 to $38.00. They now have a "buy" rating on the stock.
Medium
Report
Olema Pharmaceuticals (OLMA) had its price target lowered by HC Wainwright from $45.00 to $38.00. They now have a "buy" rating on the stock.
3/9
11:05 am
olma
Olema Pharmaceuticals (OLMA) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
High
Report
Olema Pharmaceuticals (OLMA) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
3/3
04:30 pm
olma
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
07:02 pm
olma
How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]
Low
Report
How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors [Yahoo! Finance]
2/27
04:15 pm
olma
Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure [Yahoo! Finance]
Low
Report
Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure [Yahoo! Finance]
2/24
04:59 am
olma
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit [Yahoo! Finance]
Low
Report
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit [Yahoo! Finance]
2/19
04:30 pm
olma
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Low
Report
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference